Comparative analysis of the lung microbiota in patients with respiratory infections, tuberculosis, and lung cancer: A preliminary studyOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This preliminary study compared the lung microbiota and airway immune profile across three common respiratory diseases. Researchers collected bronchoalveolar lavage fluid from each patient. They sequenced bacteria with a MiSeq system and measured 27 cytokines, chemokines, and growth factors in the same fluid using a multiplex bead-based panel, then linked microbiota to inflammation.
Who was studied?
The study enrolled 78 patients in China: 49 with community-acquired pneumonia, 21 with primary pulmonary tuberculosis, and 8 with newly diagnosed lung cancer. All were treatment-naive and clinically diagnosed at first examination. Groups did not differ in age, sex, body mass index, smoking history, comorbidities, or eating habits. The lung cancer cases were confirmed as non-small cell lung cancer.
What were the most important findings?
Sequencing yielded 3,281 bacterial phylotypes, dominated by the phyla Firmicutes, Bacteroidetes, Proteobacteria, Actinobacteria, and Fusobacteria. Bacterial diversity was highest in lung cancer and lowest in pneumonia, where the Shannon index dropped significantly. Overall beta diversity did not differ significantly among groups (ADONIS p>0.05). LEfSe found 24 genera differing between cancer and pneumonia. Of 27 cytokines, 14 differed across the three diseases, including IL-6, IL-8, IL-17, and TNF-alpha, and airway cytokines were highest in tuberculosis.
What are the greatest implications of this study?
The findings link distinct lung microbiota patterns to the local inflammatory response in tuberculosis, pneumonia, and lung cancer. The differential genera identified could serve as candidate biomarkers to help tell these respiratory disorders apart. The sample was small, especially the 8 lung cancer cases, so results are preliminary. The study is associative and cannot show whether microbiota shifts drive disease or simply accompany it.